CRL·Charles River Laboratories International, Inc.
CRL|Analyst Targets
CRL|Company Info
CRL|Insider Trading
CRL|Fundamentals
CRL|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.97 | - | - |
| Q2'26 | $2.76 | $3.02 | +9.4% |
| Q1'26 | $1.94 | $2.06 | +6.0% |
| Q4'25 | $2.56 | $2.39 | -6.6% |
| Q3'25 | $2.34 | $2.43 | +3.9% |
| Q2'25 | $2.55 | $3.12 | +22.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $968M | - | - |
| Q2'26 | $984M | $1.0B | +2.0% |
| Q1'26 | $987M | $996M | +0.9% |
| Q4'25 | $998M | $994M | -0.4% |
| Q3'25 | - | $1.0B | - |
| Q2'25 | - | $1.0B | - |
CRL|Monthly Returns
Market Data
CRL Stock Snapshot
- Market cap
- 14.30B
- Day range
- $295.15 – $303.15
- News sentiment
- 59/100 · Neutral
- Analyst target
- $313.20 (+4.7%)
- Consensus
- Buy · 25 analysts
CRL's technical picture is constructive, with trend and momentum pointing the same direction. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Reverse DCF
What growth is priced into CRL?
At today's price, Charles River Laboratories International, Inc. needs to grow free cash flow about 23.9% a year for the next 10 years to justify its valuation at a 9.89% cost of capital. Over its actual history it has compounded free cash flow at 10.1% a year, so the market is asking for 13.9 percentage points above its own delivered rate. On that basis CRL looks priced above what its own growth record supports.
- Implied FCF growth
- 23.9%
- Historical FCF CAGR
- 10.1%
- Growth gap
- +13.9 pts
- Verdict
- RICH
- Discount rate (WACC)
- 9.89%
- Beta
- 1.09
Behaviour On Record
What CRL's own history says about today's numbers
- Realized volatility (21d)
- 38.4% 74th pct
- Below its peak
- -34.2%
- vs 200-day average
- +42.2%
- Up days (1y)
- 54%
Charles River Laboratories International, Inc. is currently running 38.4% annualised volatility over the last 21 sessions. Measured against CRL's own 13 years of daily returns rather than a market-wide average, that is the 74th percentile — a little above its own norm, against a typical reading of 29.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
CRL is trading -34.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -25.2%, and the deepest was -49.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +42.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 99th percentile — a wider gap than this stock usually carries. Over the past year CRL closed higher on 54% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, CRL finished the month higher 8 of 13 times, with a median return of +3.4% and an average of +0.1%. Its strongest month historically has been July at +6.8% on average, its weakest April at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: CRL has opened more than 2% away from the prior close in 168 of 3,266 sessions (5.1% of the time), with the largest gaps running +7.1% and -13.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, CRL moved an average of 2.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.4% and a largest of +3.9%.
All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against CRL's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CRL's sector?
Charles River Laboratories International, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
Analyst Rating Changes
Are analysts turning bullish or bearish on CRL?
Morgan Stanley most recently reiterated its rating on Charles River Laboratories International, Inc. to Overweight on Oct 13, 2026 with a price target of $340 (from $300). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.
- Latest action
- Morgan Stanley — Overweight
- 90-day upgrades
- 1
- 90-day downgrades
- 1
- Net rating momentum
- 0
Peers & ETF holders
CRL peers & ETF holders
Diagnostics & ResearchMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 5,887,175 | 12.31% | $1.17B | 2026-01-29 |
| FMR LLC (Fidelity) | ▲ Buy | 4,239,752 | 8.86% | $961.53M | 2026-08-13 |
| BlackRock, Inc. | ▼ Sell | 3,798,560 | 7.94% | $861.48M | 2026-08-07 |
| Invesco Ltd. | ▲ Buy | 2,984,785 | 6.24% | $676.92M | 2026-08-14 |
| Harris Associates L P | ▲ Buy | 2,241,144 | 4.69% | $508.27M | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 1,305,738 | 2.73% | $295.60M | 2026-08-12 |
| Wellington Management Group LLP | ▼ Sell | 1,288,463 | 2.69% | $292.21M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 1,193,601 | 2.50% | $270.70M | 2026-09-02 |
| Bank of America Corp | ▲ Buy | 1,172,586 | 2.45% | $265.93M | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 862,704 | 1.80% | $195.63M | 2026-08-13 |
| Morgan Stanley | ▼ Sell | 800,487 | 1.67% | $181.54M | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 639,803 | 1.34% | $145.10M | 2026-08-14 |
| Millennium Management LLC | ▼ Sell | 486,462 | 1.02% | $110.32M | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 446,092 | 0.93% | $101.17M | 2026-08-13 |
| Gotham Asset Management, LLC | ▲ Buy | 433,146 | 0.91% | $98.23M | 2026-08-14 |
| Norges Bank | ▼ Sell | 370,040 | 0.77% | $83.92M | 2026-08-12 |
| Marshall Wace, LLP | ▲ Buy | 342,995 | 0.72% | $77.79M | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 316,217 | 0.66% | $71.71M | 2026-08-03 |
| JPMorgan Chase & Co | ▲ Buy | 286,317 | 0.60% | $65.09M | 2026-08-12 |
| AllianceBernstein L.P. | ▲ Buy | 374,585 | 0.78% | $64.62M | 2026-08-14 |
| Loomis Sayles & Co L P | ▲ Buy | 223,668 | 0.47% | $50.73M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 213,480 | 0.45% | $48.42M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 93,225 | 0.19% | $21.14M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 44,344 | 0.09% | $9.97M | 2026-08-14 |
| Prudential Financial Inc | ▼ Sell | 32,465 | 0.07% | $7.36M | 2026-08-12 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-05-08 | 2025-06-22 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $15K - $50K | 2025-04-08 | 2025-05-08 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-01-15 | 2025-02-12 |